Company research / KNSA
Kiniksa Pharmaceuticals International, plc (KNSA)
- Sector Manufacturing
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M. Revenue grew 60.1% from the prior annual period.
Key ratios (year ended 2025-12-31)
11.4%
Operating margin
8.7%
Net margin
10.4%
Return on year-end equity
60.1%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.